Nucleic acids: Bringing Breakthroughs to Life—faster

From Breakthrough to Reality: How BioSpring Fuels Biotech Innovation

From gene editing to antisense therapies, nucleic acid-based medicines are transforming the future of medicine. Yet, turning groundbreaking research into real-world treatments remains one of the biggest challenges in biotech. BioSpring is the partner that makes this transition seamless.

The synthesis of nucleic acids is highly complex, especially as regulatory requirements continue to evolve. With nearly 30 years of experience, BioSpring is one of the few providers offering fully integrated manufacturing and analytical services for nucleic acids.

Our expertise accelerates the journey from discovery to clinical trials and beyond—helping companies bring life-changing therapies to patients faster.

Speed and Scalability: A Critical Success Factor
In biotech, time is everything. Companies developing nucleic acid therapeutics must transition rapidly from early research to clinical and commercial production—without compromising on quality or compliance. BioSpring’s platform-based approach enables rapid scale-up while ensuring exceptional purity and consistency. By supporting every phase of drug development—from high-throughput synthesis to GMP manufacturing—BioSpring helps pharma and biotech companies optimize processes, meet regulatory requirements, and achieve critical milestones faster.

Growing Market
The market for therapeutic nucleic acids continues to grow. Global annual growth for therapeutic oligonucleotides e.g. is estimated to reach more than 20%, depending on the source. The statistics confirm this progress. At the end of 2024, 24 therapeutics based on oligonucleotides had already been approved worldwide, but above all: just six of these were approved in the 19 years between 1998 and 2017, six more were approved in 2023 alone. This illustrates the rapid pace of development.

Quality Is Non-Negotiable
In nucleic acid therapeutics, quality is not an option—it’s the foundation of success. At BioSpring, we hold ourselves to the highest standards, ensuring every molecule we produce meets stringent regulatory criteria.

With extensive analytical capabilities, a track record of successful FDA audits, and continuous investment in innovation, BioSpring guarantees the integrity, safety, and reliability of nucleic acid drug substances.
Learn more about how BioSpring supports biotech innovation at:

^{* Advertisement - in cooperation with BioSpring GmbH*}